Claims:

1. A combined agent, said agent comprising *cis*-hydroxyproline (CHP) and gemcitabine.

2. The agent according to claim 1,
characterized in that
it comprises a pharmaceutically acceptable carrier, adjuvant and/or vehicle.

3. The agent according to claim 2,
characterized in that
the carrier is selected from the group comprising fillers, diluents, binders, humectants, disintegrants, dissolution retarders, absorption enhancers, wetting agents, adsorbents and/or lubricants.

4. The agent according to claim 2,
characterized in that
the vehicles are selected from the group comprising liposomes, siosomes and/or niosomes.

5. The agent according to any of claims 1 to 4,
characterized in that
the agent is a gel, poudrage, powder, infusion solution, tablet, sustained-release tablet, premix, a prodrug, emulsion, brew-up formulation, drops, a concentrate, granulate, syrup, pellet, bolus, capsule, aerosol, spray and/or inhalant.

6. The agent according to claim 5,
characterized in that

CHP and gemcitabine are present in a formulation at a concentration of 0.1 to 99.5, preferably 0.5 to 95, and more preferably 20 to 80 wt.-%.

7. The agent according to any of claims 1 to 6,
characterized in that
CHP and gemcitabine are present in said formulation at a ratio of from 500:1 to 1:500, preferably from 100:1 to 1:100, and more preferably from 50:1 to 1:50.

8. An anti-tumor agent,
characterized in that
it comprises a combined agent according to any of claims 1 to 7.

9. Use of the agent according to any of claims 1 to 8 in the prophylaxis, therapy, follow-up and/or aftercare of diseases associated with cell growth, cell differentiation and/or cell division.

10. The use according to the preceding claim,
characterized in that
the disease is a tumor.

11. The use according to claim 9 or 10,
characterized in that
tumor growth, tumor spreading, tumor angiogenesis, tumor invasion, tumor infiltration and/or tumor metastasization are inhibited or prevented.

12. The use according to the preceding claim,
characterized in that

the tumor diseases are selected from the group of neoplastic tumors, inflammatory tumors and/or abscesses, effusions and/or edemas.

13. The use according to any of claims 10 to 12, characterized in that the tumor is a solid tumor or a leukemia.

14. The use according to the preceding claim, characterized in that the solid tumor is a tumor of the urogenital tract and/or gastrointestinal tract.

15. The use according to any of claims 10 to 14, characterized in that the tumor is a colon carcinoma, stomach carcinoma, pancreas carcinoma, small intestine carcinoma, ovarian carcinoma, cervical carcinoma, lung carcinoma, prostate carcinoma, mammary carcinoma, renal cell carcinoma, a brain tumor, head-throat tumor, liver carcinoma, and/or a metastase of the above tumors.

16. The use according to claim 13 or 14, characterized in that the solid tumor is a mammary, bronchial, colorectal, and/or prostate carcinoma and/or a metastase of the above tumors.

17. The use according to claim 14, characterized in that the tumor of the urogenital tract is a bladder carcinoma and/or a metastase of such tumors.

18. The use according to any of claims 9 to 17,

characterized in that
said follow-up is monitoring the effectiveness of an anti-tumor treatment.

19. The use according to any of claims 9 to 18,
characterized in that
the agents according to claims 1 to 8 are employed in the prophylaxis, prevention, diagnosis, attenuation, therapy, follow-up and/or aftercare of tumor metastasization, tumor invasion, tumor growth, tumor spreading, tumor infiltration and/or tumor angiogenesis.

20. The use according to any of claims 9 to 19,
characterized in that
said follow-up is monitoring the effectiveness of an anti-tumor treatment.

21. The use according to any of claims 9 to 20,
characterized in that
the agents according to claims 1 to 8 are used in a combined therapy.

22. The use according to the preceding claim,
characterized in that
said combined therapy comprises a chemotherapy, a treatment with cytostatic agents and/or a radiotherapy.

23. The use according to the preceding claim,
characterized in that
the combined therapy comprises an adjuvant, biologically specified form of therapy.

24. The use according to the preceding claim,
characterized in that

said form of therapy is an immune therapy.

25. The use according to any of claims 9 to 24 to increase the sensitivity of tumor cells to cytostatic agents and/or radiation.

26. The use according to any of claims 9 to 25 for inhibiting the viability, the proliferation rate of cells, for inducing apoptosis and/or cell cycle arrest.

27. The use according to any of claims 9 to 26,
characterized in that
the preparation is employed orally, vaginally, rectally, nasally, subcutaneously, intravenously, intramuscularly, intraperitoneally, regionally and/or topically.

28. The use according to any of claims 9 to 27,
characterized in that
the agents according to claims 1 to 8 are employed in overall amounts of from 0.05 to 1000 mg per kg, preferably from 5 to 450 mg per kg body weight per 24 hours.